SPTX | Ticker Profile - Titan Protect

SPTX

Seaport Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$16.44

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$957M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-7.46

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-28.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$35.00

+113% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines. The company develops therapeutic candidates for conditions such as depression and anxiety disorders using its proprietary Glyph technology platform. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and other side effects. All therapeutic candidates in development are based on this platform, with research and development activities focused on neuropsychiatric medicines. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors. The company was founded in 2024 and is based in Boston, Massachusetts.

https://www.seaporttx.com

Country: United States Employees: 58 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$23.00

29% below the year high

52W Low

$14.85

11% above the year low

Avg Volume

626,794

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

2.9%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.94

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

17.46

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

17.13

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-50,781,500

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-74,881,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$42.00

Target Median

$35.00

Target Low

$30.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go